RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Gilead Sciences (NASDAQ: GILD) and believes the company's HIV products ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE